Safety
neutropenia, diarrhea, thrombocytopenia, proteinuria, leucopenia, deaths, hypertension, hand‐foot syndrome
NEUTROPENIA, ADVERSE EVENTS, ADVERSE EVENT, THROMBOCYTOPENIA, LEUCOPENIA, HYPERTENSION
The most common adverse events (AEs) were neutropenia (41.94%, 13/31), followed by leucopenia (35.48%, 11/31), and thrombocytopenia (25.81%, 8/31). The other common AEs were proteinuria (22.58%, 7/31), diarrhea (22.58%, 7/31), hypertension (22.58%, 7/31), and hand‐foot syndrome (22.58%, 7/31). Almost all the patients had different AEs, but most of the AEs were mild and tolerable. The incidence of grade 3–4 AEs was observed in 12 (38.71%) patients, of which neutropenia (19.35%, 6/31), leucopenia (9.68%, 3/31), and proteinuria (6.45%, 2/31) were most common. The apatinib‐related AEs, proteinuria, hypertension, and hand‐foot syndrome, were tolerable. No treatment‐related deaths were reported. The AEs are described in Table Adverse events during the treatment phase in 31 patientsAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.